menu
    • menu
    [{"orgOrder":0,"company":"MicuRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Contezolid Acefosamil","moa":"70s ribosome","graph1":"Podiatry","graph2":"Phase I","graph3":"MicuRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"MicuRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MicuRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioStem Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Amniotic Tissue Allograft","moa":"IL-1 receptor","graph1":"Podiatry","graph2":"Phase I","graph3":"BioStem Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical","sponsorNew":"BioStem Technologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioStem Technologies \/ Inapplicable"},{"orgOrder":0,"company":"BioStem Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Other Large Molecule","year":"2025","type":"Inapplicable","leadProduct":"Amniotic Tissue Allograft","moa":"IL-1 receptor","graph1":"Podiatry","graph2":"Phase I","graph3":"BioStem Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical","sponsorNew":"BioStem Technologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioStem Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cymerus Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I","graph3":"Cynata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Dressing","sponsorNew":"Cynata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cynata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cymerus Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I","graph3":"Cynata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Dressing","sponsorNew":"Cynata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cynata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Cymerus Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I","graph3":"Cynata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Dressing","sponsorNew":"Cynata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cynata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Cymerus Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I","graph3":"Cynata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Dressing","sponsorNew":"Cynata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cynata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioStem Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Amniotic Chorion Tissue Allograft","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I","graph3":"BioStem Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioStem Technologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioStem Technologies \/ Inapplicable"},{"orgOrder":0,"company":"CellResearch Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"SINGAPORE","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Human Umbilical Cord Derived Mesenchymal Stem Cell","moa":"ACE2 receptor","graph1":"Podiatry","graph2":"Phase I","graph3":"CellResearch Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CellResearch Corporation \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CellResearch Corporation \/ Inapplicable"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            MicuRx Pharmaceuticals

                            U.S.A arrow
                            China Battery Fair
                            Not Confirmed

                            MicuRx Pharmaceuticals

                            U.S.A arrow
                            China Battery Fair
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Contezolid Acefosamil

                            Therapeutic Area : Podiatry

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MicuRx: Contezolid Phase III Trial Endorsed, Promising for Diabetic Foot Infection

                            Details : MRX-4 (contezolid acefosamil) is being evaluating in the late-stage clinical trials studies for the treatment of patients suffering from Diabetic Foot Infection.

                            Product Name : MRX-4

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            February 25, 2025

                            Lead Product(s) : Contezolid Acefosamil

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            BioStem Technologies

                            U.S.A arrow
                            China Battery Fair
                            Not Confirmed

                            BioStem Technologies

                            U.S.A arrow
                            China Battery Fair
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amniotic Tissue Allograft

                            Therapeutic Area : Podiatry

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BioStem Launches Trial for BioREtain® Technology in Diabetic Foot Ulcers

                            Details : Vendaje is a structural tissue allograft composed of the amnion layer of the placental membrane. It is being investigated for diabetic foot ulcers.

                            Product Name : Vendaje

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            January 08, 2025

                            Lead Product(s) : Amniotic Tissue Allograft

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cynata Therapeutics

                            Australia arrow
                            China Battery Fair
                            Not Confirmed

                            Cynata Therapeutics

                            Australia arrow
                            China Battery Fair
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cymerus Mesenchymal Stem Cell

                            Therapeutic Area : Podiatry

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cynata Therapeutics Completes Enrollment in Phase 1 Trial of CYP-006TK for Foot Ulcers

                            Details : CYP-006TK is a topical wound dressing, cell and gene therapy drug candidate, which is currently being evaluated for the treatment of patients with diabetic foot ulcers.

                            Product Name : CYP-006TK

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            September 04, 2024

                            Lead Product(s) : Cymerus Mesenchymal Stem Cell

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            BioStem Technologies

                            U.S.A arrow
                            China Battery Fair
                            Not Confirmed

                            BioStem Technologies

                            U.S.A arrow
                            China Battery Fair
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amniotic Tissue Allograft

                            Therapeutic Area : Podiatry

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BioStem Receives IRB Approval to Study Vendaje® for Diabetic Foot Ulcers

                            Details : Vendaje is a structural tissue allograft composed of the amnion layer of the placental membrane. It is being investigated for diabetic foot ulcers.

                            Product Name : Vendaje

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            August 21, 2024

                            Lead Product(s) : Amniotic Tissue Allograft

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Recce Pharmaceuticals

                            Australia arrow
                            China Battery Fair
                            Not Confirmed

                            Recce Pharmaceuticals

                            Australia arrow
                            China Battery Fair
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : R327

                            Therapeutic Area : Podiatry

                            Study Phase : Phase I

                            Sponsor : US Department of Defense

                            Deal Size : $2.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Recce Receives $2M US Defense Grant for RECCE® 327 Gel

                            Details : The funding aims to accelerate the development of RECCE 327 Gel (R327) for acute treatment of burn wound infections and downstream bacterial complications such as sepsis in a military setting.

                            Product Name : RECCE 327

                            Product Type : Antibiotic

                            Upfront Cash : Undisclosed

                            July 16, 2024

                            Lead Product(s) : R327

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase I

                            Sponsor : US Department of Defense

                            Deal Size : $2.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Recce Pharmaceuticals

                            Australia arrow
                            China Battery Fair
                            Not Confirmed

                            Recce Pharmaceuticals

                            Australia arrow
                            China Battery Fair
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : R327

                            Therapeutic Area : Podiatry

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Recce Pharmaceuticals Expands RECCE® 327 Gel Trials for Skin Infections

                            Details : R327 (RECCE-327) is a fast-acting anti-infective effective against Gram-positive & negative bacteria. It is under development for the treatment of acute bacterial skin and skin structure infections.

                            Product Name : RECCE 327

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            June 25, 2024

                            Lead Product(s) : R327

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Cynata Therapeutics

                            Australia arrow
                            China Battery Fair
                            Not Confirmed

                            Cynata Therapeutics

                            Australia arrow
                            China Battery Fair
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cymerus Mesenchymal Stem Cell

                            Therapeutic Area : Podiatry

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Encouraging Initial Data from CYP-006TK Diabetic Foot Ulcer Clinical Trial

                            Details : CYP-006TK consists of allogenic mesenchymoangioblast-derived mesenchymal stem cells or Cymerus™ MSCs, seeded onto a heptylamine plasma polymer-coated silicone dressing for diabetic foot ulcers.

                            Product Name : CYP-006TK

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            February 26, 2024

                            Lead Product(s) : Cymerus Mesenchymal Stem Cell

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            BioStem Technologies

                            U.S.A arrow
                            China Battery Fair
                            Not Confirmed

                            BioStem Technologies

                            U.S.A arrow
                            China Battery Fair
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amniotic Chorion Tissue Allograft

                            Therapeutic Area : Podiatry

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BioStem Begins Trial for BioREtain® in Diabetic Foot Ulcers

                            Details : BR-AC is a structural tissue allograft composed of the amnion layer of the placental membrane. It is being investigated for diabetic foot ulcers.

                            Product Name : BR-AC

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            February 10, 2024

                            Lead Product(s) : Amniotic Chorion Tissue Allograft

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            CellResearch Corporation

                            Singapore arrow
                            China Battery Fair
                            Not Confirmed

                            CellResearch Corporation

                            Singapore arrow
                            China Battery Fair
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human Umbilical Cord Derived Mesenchymal Stem Cell

                            Therapeutic Area : Podiatry

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cell Research Corporation (CRC) Announces Positive Results of Phase I Study for CorLiCyte®

                            Details : CorLiCyte® is a live mesenchymal stem cell therapy derived from human umbilical cord lining stem cells, with a proprietary optimised expression of cytokines, growth and cellular factors for the treatment of a number of serious health conditions.

                            Product Name : CorLiCyte

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            September 16, 2022

                            Lead Product(s) : Human Umbilical Cord Derived Mesenchymal Stem Cell

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth